Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects

被引:193
作者
Evers, B. [1 ]
Jonkers, J. [1 ]
机构
[1] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands
关键词
BRCA1; BRCA2; breast cancer; tumor suppressor; mouse model;
D O I
10.1038/sj.onc.1209871
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Germline mutations in BRCA1 and BRCA2 are responsible for a large proportion of hereditary breast and ovarian cancers. Soon after the identification of both genes in the mid-1990s, investigators set out to develop mouse models for the associated disease. Whereas conventional Brca1 and Brca2 mouse mutants did not reveal a strong phenotype in a heterozygous setting, most homozygous mutations caused embryonic lethality. Consequently, development of mouse models for BRCA-associated tumorigenesis required the generation of tissue-specific conditional knockout animals. In this review, we give an overview of the conventional and the conditional mouse models of BRCA1 and BRCA2 deficiency generated over the last decade, as well as the contribution of these models to our understanding of the biological and molecular functions of BRCA1 and BRCA2. The most advanced mouse models for BRCA1- and BRCA2-associated tumorigenesis mimic human disease to the extent that they can be used in studies addressing clinically relevant questions. These models will help to resolve yet unanswered questions and to translate our increasing knowledge of BRCA1 and BRCA2 biology into clinical practice.
引用
收藏
页码:5885 / 5897
页数:13
相关论文
共 125 条
  • [1] Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003
  • [2] Bachelier R, 2005, ONCOL REP, V14, P1117
  • [3] BRCA1 regulates gene expression for orderly mitotic progression
    Bae, I
    Rih, JK
    Kim, HJ
    Kang, HJ
    Haddad, B
    Kirilyuk, A
    Fan, SJ
    Avantaggiati, ML
    Rosen, EM
    [J]. CELL CYCLE, 2005, 4 (11) : 1641 - 1666
  • [4] Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
    Bell, DW
    Varley, JM
    Szydlo, TE
    Kang, DH
    Wahrer, DCR
    Shannon, KE
    Lubratovich, M
    Verselis, SJ
    Isselbacher, KJ
    Fraumeni, JF
    Birch, JM
    Li, FP
    Garber, JE
    Haber, DA
    [J]. SCIENCE, 1999, 286 (5449) : 2528 - 2531
  • [5] Bennett LM, 2000, MOL CARCINOGEN, V28, P174, DOI 10.1002/1098-2744(200007)28:3<174::AID-MC6>3.0.CO
  • [6] 2-C
  • [7] Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues
    Berton, TR
    Matsumoto, T
    Page, A
    Conti, CJ
    Deng, CX
    Jorcano, JL
    Johnson, DG
    [J]. ONCOGENE, 2003, 22 (35) : 5415 - 5426
  • [8] Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice.
    Blackshear, PE
    Goldsworthy, SM
    Foley, JF
    McAllister, KA
    Bennett, LM
    Collins, NK
    Bunch, DO
    Brown, P
    Wiseman, RW
    Davis, BJ
    [J]. ONCOGENE, 1998, 16 (01) : 61 - 68
  • [9] Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice
    Brodie, SG
    Xu, XL
    Qiao, WH
    Li, WM
    Cao, L
    Deng, CX
    [J]. ONCOGENE, 2001, 20 (51) : 7514 - 7523
  • [10] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    Bryant, HE
    Schultz, N
    Thomas, HD
    Parker, KM
    Flower, D
    Lopez, E
    Kyle, S
    Meuth, M
    Curtin, NJ
    Helleday, T
    [J]. NATURE, 2005, 434 (7035) : 913 - 917